(crizotinib) Capsules, Oral
XALKORI (crizotinib) is an oral receptor tyrosine kinase inhibitor. The molecular formula for crizotinib is C21H22Cl2FN5O. The molecular weight is 450.34 Daltons. Crizotinib is described chemically as (R)-3-[l-(2,6-Dichloro-3 -fluorophenyl)ethoxy] -5- [ 1 -(piperidin-4-yl)- 1H-pyrazol-4-yl]pyridin-2-amine.
The chemical structure of crizotinib is shown below:
Crizotinib is a white to pale-yellow powder with a pKa of 9.4 (piperidinium cation) and 5.6 (pyridinium cation). The solubility of crizotinib in aqueous media decreases over the range pH 1.6 to pH 8.2 from greater than 10 mg/mL to less than 0.1 mg/mL. The log of the distribution coefficient (octanol/water) at pH 7.4 is 1.65.
XALKORI capsules are supplied as printed hard-shell capsules containing 250 mg or 200 mg of crizotinib together with colloidal silicon dioxide, microcrystalline cellulose, anhydrous dibasic calcium phosphate, sodium starch glycolate, magnesium stearate, and hard gelatin capsule shells as inactive ingredients.
The pink opaque capsule shell components contain gelatin, titanium dioxide, and red iron oxide. The white opaque capsule shell components contain gelatin, and titanium dioxide. The printing ink contains shellac, propylene glycol, strong ammonia solution, potassium hydroxide, and black iron oxide.
What are the possible side effects of crizotinib (Xalkori)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using crizotinib and call your doctor at once if you have a serious side effect such as:
- severe dizziness, fainting, fast or pounding heartbeats;
- vision problems such as blurred vision, increased sensitivity of your eyes to light, or seeing flashes of light or "floaters";
- chest pain, dry cough or cough with mucus, wheezing, feeling short of breath;
- easy bruising, unusual bleeding...
Last reviewed on RxList: 3/15/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Xalkori Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.